Owens & Minor reported a net loss of $150.28 million for the third quarter of 2025, a significant increase from a net loss of $12.77 million in the prior year. Revenue from continuing operations increased slightly to $697.3 million, up from $686.8 million in Q3 2024. The company's GAAP EPS from continuing operations was a loss of $0.07, while non-GAAP adjusted EPS from continuing operations was $0.25. The company is strategically reshaping its organization around its Patient Direct platform, focusing on long-term growth opportunities within home-based care.

Owens & Minor delivered Q2 2025 revenue growth in continuing operations, driven by Patient Direct performance. Despite improved adjusted operating income and adjusted EBITDA, the company reported a significant GAAP net loss due to transaction breakage fees and discontinued operations charges. The Products & Healthcare Services segment was classified as discontinued operations.

Owens & Minor reported a slight increase in revenue to $2.632 billion for Q1 2025, up from $2.613 billion in Q1 2024. The company experienced a net loss of $24.982 million, or $0.32 per common share, but reported adjusted net income of $18.073 million, or $0.23 per share. The Patient Direct segment showed strong performance with mid-single digit top-line growth and mid-teen expansion in EBITDA.

Owens & Minor reported financial results for the fourth quarter and year ended December 31, 2024. The company is pleased with the progress that they have made against the strategy as outlined at Investor Day in December 2023. They committed to optimizing their Products & Healthcare Services business, leveraging their leading Patient Direct platform, and building balance sheet flexibility through deleveraging. Active discussions are underway regarding the potential sale of Products & Healthcare Services (P&HS) Segment. Board of Directors authorized share repurchase program of up to $100 Million.

Owens & Minor reported a 5% increase in consolidated revenue, reaching $2.7 billion. The company experienced a GAAP net loss of $(13) million, but achieved an adjusted EPS of $0.42. Adjusted EBITDA grew by 5% to $142 million, and total debt was reduced by $198 million.

Owens & Minor reported a 4% increase in consolidated revenue, driven by growth in both the Products & Healthcare Services and Patient Direct segments. The company generated $116 million in operating cash flow, which enabled a $71 million debt reduction. However, the company reported a net loss of $(32) million, or $(0.42) per share.

Owens & Minor reported a 4% increase in consolidated revenue to $2.6 billion for Q1 2024. GAAP operating margin was flat, but adjusted operating margin expanded by 31 basis points. The company experienced a net loss per share of $(0.29), but adjusted earnings per share reached $0.19.

Owens & Minor reported a strong finish to 2023 with top-line growth across both business segments, robust profit growth, and exceptional operating cash flow. The Patient Direct segment outperformed the market, and the Products and Healthcare Services segment displayed meaningful sequential revenue and profit improvements.

Owens & Minor reported a 5% increase in revenue for Q4 2021, driven by growth in both the Global Solutions and Global Products segments. The company's adjusted net income was $61 million, reflecting revenue growth and the ability to manage inflationary pressures. The company is reaffirming its 2022 financial guidance and the acquisition of Apria remains on track.

Owens & Minor reported strong Q4 2020 results with revenue growth of 8% year-over-year and significant increases in GAAP EPS and Adjusted EPS. The company benefited from increased demand for PPE and strong performance in its home healthcare business. They also reduced total debt by $303 million in the fourth quarter.

Owens & Minor reported a strong third quarter, driven by exceptional operating performance. The company's financial profile is strong, allowing investments in technology and infrastructure while deleveraging the balance sheet. They increased full year adjusted EPS guidance and reconfirmed expectation of double digit adjusted EPS growth in 2021.

Owens & Minor reported improved financial performance in Q2 2020, driven by increased productivity, manufacturing output related to PPE, and capitalizing on an earlier than expected increase in elective procedures. The company doubled its full-year adjusted EPS guidance and reconfirmed its expectation of double-digit adjusted EPS growth in 2021.

Owens & Minor reported a decrease in revenue due to customer non-renewals and reduced surgical procedures, which was partially offset by increased PPE sales and growth in Home Healthcare. The company generated $93 million in operating cash flow and reduced total debt by $24 million. They also re-confirmed their full year adjusted EPS guidance of $0.50 to $0.60.